Quick answer
What should a new researcher know about BPC-157? It is a synthetic 15-residue peptide (about 1419 g/mol) with a mostly preclinical literature. A 2025 systematic review included 36 studies, 35 of them preclinical, rated the evidence level IV and V, and found no clinical safety data. Judge any paper by who ran it, its controls, its pre-specified endpoint, how the material was verified and whether the conclusion fits the model. Use the calculator and the COA page. For laboratory research use only.
BPC-157 has an unusual literature: large in volume, concentrated in a small number of laboratories, mostly preclinical, and often summarized in much more confident language than the underlying studies support. This introduction is for a researcher meeting the compound for the first time. It covers what the molecule is, what the one systematic review of the musculoskeletal literature found and did not find, the model systems that dominate, and a short list of questions to ask of any BPC-157 paper. The goal is a reader who can evaluate the claims, not one who repeats them. Nothing here describes a use outside the laboratory.
What BPC-157 is
The BPC-157 product page describes a synthetic pentadecapeptide, a chain of fifteen amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The page says the sequence corresponds to a partial segment of a larger protein first isolated from gastric juice, which is where the name "Body Protection Compound" comes from, that the peptide is made by solid-phase synthesis and does not occur as a free molecule in nature, and that its small size, proline-rich core and good aqueous solubility make it easy to handle at the bench. The listed form is a 10 mg lyophilized powder in a sealed clear glass research vial, purity ≥98% by HPLC, stored at 2–8 °C or −20 °C for long-term holding, protected from heat, moisture and light. The average molar mass computed from the sequence is about 1419 g/mol.
Two points about the molecule shape every experiment. It is small and proline-rich, which usually means good solubility and a lack of stable folded structure, so handling problems are more likely to be oxidation or adsorption than aggregation. And, because the name refers to a gastric-juice protein, searching the literature for "BPC" without the number can return unrelated hits; the 157 matters.
Reading the literature: its shape
The most useful single document is a systematic review of the musculoskeletal literature. Its authors identified 544 articles from 1993 to 2024 and, after removing duplicates, included 36 studies, 35 preclinical and one clinical. They reported that the studies suggest BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines, and that in preclinical models it improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries. They also reported that the single clinical report was a retrospective study of 12 individuals, that preclinical safety studies showed no adverse effects across several organ systems, and that no clinical safety data were found (Vasireddi et al., 2025). The review's own conclusion is that the evidence is level IV and V, and that adverse effects are possible given unregulated manufacturing, contamination or unknown clinical safety.
| Feature of the literature | What the review reports | What it implies for a researcher |
|---|---|---|
| Volume | 544 articles identified, 36 included | The reviewed set is modest in size |
| Study type | 35 preclinical, 1 clinical | Nearly all findings are animal or cell data |
| Evidence level | Level IV and V | Suggestive, not confirmatory |
| Safety data | Preclinical organ-system safety studies; no clinical safety data | Absence of reported harm in animals is not a safety conclusion |
| Mechanism | Growth hormone receptor expression, growth and angiogenesis pathways, cytokines | Proposed pathways, to be tested individually |
The earlier primary papers show the same pattern at a finer grain. A 2003 study examined a transected rat Achilles tendon and reported effects on tendon cell growth in vitro as well (Staresinic et al., 2003). A 2014 study on tendon fibroblasts isolated from rat Achilles tendon used cDNA microarray analysis to identify growth hormone receptor as a gene whose expression was altered by BPC-157 (Chang et al., 2014). Reviews of gastrointestinal work describe BPC-157 against the background of standard angiogenic growth factors (Seiwerth et al., 2018) and of the brain-gut axis (Sikiric et al., 2016). Each is one model, reported by one group.
Where the model systems sit
| Model family | Typical question | Main readouts | Where to read more in the library |
|---|---|---|---|
| Tendon and ligament fibroblasts | Does the peptide alter cell growth, migration or gene expression? | Proliferation, scratch closure, transcript profiling | BPC-157 research overview |
| Rodent soft-tissue injury | Does repair of a defined injury change? | Histology, biomechanical testing, functional scores | BPC-157 vs TB-500 |
| Gastrointestinal models | Does mucosal integrity or healing change? | Lesion scoring, histology | combination research |
| Endothelial and angiogenesis assays | Does the peptide affect vessel formation? | Tube formation, vessel density | overview |
Five questions to ask of any BPC-157 paper
- Who ran it? Check whether the group has authored many of the other papers on the compound. Authorship overlap does not invalidate a result, but independent replication is the strongest form of confirmation, and a paper from a new group that confirms a result carries more weight than a further paper from the original one.
- What is the control? A vehicle prepared in the same diluent, and ideally a scrambled-sequence peptide. A study with no vehicle arm can show only that a condition changed over time.
- What is the endpoint, and was it pre-specified? Functional and biomechanical outcomes are stronger than a single histology score. Several outcomes tested with no correction for multiplicity raise the false-positive risk.
- How was the material verified? Look for an independent identity and purity check of the material used, not only a statement of its source. A result obtained with an unverified vial is a result about the vial.
- Does the conclusion match the model? A rat tendon result informs tendon-cell biology in that model. Reading it as a statement about another species is an extrapolation the data do not make.
A first experiment, designed properly
For a laboratory that wants to test a published finding, a fibroblast experiment is the lowest-cost entry point. Use a primary or well-characterized fibroblast line, seed at a fixed density and serum-starve briefly so that baseline growth is low. Prepare the stock from the vial by the formula concentration equals mass divided by volume, convert to molar with a molar mass of about 1419 g/mol, and dilute into medium immediately before use. Run a concentration series with vehicle and positive-control wells on every plate, and measure two independent readouts, for example scratch closure with a proliferation block, and transcript levels of a pre-chosen gene such as the growth hormone receptor. Replicate on at least three independent days. The reconstitution calculator performs the conversions; the bench workflow is in the reconstitution guide for related blends and the stability notes in BPC-157 room-temperature stability.
Two details are often missed. First, record the lot number and keep a retained aliquot so that any surprising result can be traced to the material. Second, because the peptide is small and dilute solutions adsorb to plastic, use low-binding tubes and make working dilutions fresh.
Quality checks before the first plate
The product page lists HPLC purity of ≥98% and says batch-specific documents are published on the site. Lot documents are collected on the COA page, and the interpretation of a BPC-157 trace is covered in BPC-157 purity testing and third-party testing. Remember that HPLC percentage is the share of chromatographic area occupied by the main peak, not the share of vial mass that is peptide. Counterions and moisture also take up weight, so a potency calculation from label mass overstates the true concentration by an unknown factor unless net peptide content is measured.
Related compounds and where to go next
BPC-157 is frequently combined with TB-500 and GHK-Cu in commercial blends, which raises a separate set of design questions about co-lyophilization, copper and fixed ratios. The library discusses those in does copper degrade other peptides in a blend and on the Wolverine Stack and Glow Stack product pages. The sourcing considerations are in where to buy BPC-157, and the category primer is what are research peptides. The compound sits among the other tool peptides in the research shop.
Frequently asked questions
What is BPC-157?
A synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The product page says it corresponds to a partial segment of a larger protein first isolated from gastric juice.
How large is the BPC-157 literature?
A 2025 systematic review of the musculoskeletal literature identified 544 articles from 1993 to 2024 and included 36 studies, 35 preclinical and one clinical.
What evidence level does the review assign?
Level IV and V, which the authors describe as suggestive of promise, not confirmatory.
Does the review report clinical safety data?
No. It reports that preclinical safety studies showed no adverse effects across several organ systems and that no clinical safety data were found.
What did the 2014 tendon fibroblast study find?
Using cDNA microarray analysis in fibroblasts from rat Achilles tendon, the authors identified growth hormone receptor as a gene whose expression was altered by BPC-157.
Why does replication matter for this compound?
Independent confirmation by groups other than the original authors is the strongest form of support, so authorship overlap across papers is worth checking.
What molar mass applies to BPC-157?
About 1419 g/mol computed from the sequence. Molar concentration is mass concentration divided by molar mass.
How should the vial be stored?
The product page states refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.
Is HPLC purity the same as peptide content?
No. HPLC purity is the share of the chromatographic area occupied by the main peak. Counterions and moisture also occupy vial mass.
What is a sound first experiment?
A fibroblast assay with vehicle and positive controls, two independent readouts, at least three independent days and a recorded lot number.
Research-use statement
Everything on this page is educational background for laboratory research use only. V8 Peptides products are sold as research materials, not for human or animal consumption, and nothing here describes a use outside the laboratory. Browse the research catalog, check lot documents on the COA page, or run volumes through the reconstitution calculator.
Related reading: Ordering BPC-157 and TB-500: Lab Planning Guide, BPC-157 Certificate of Analysis: A Line-by-Line Read.
References
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551
- Staresinic M, Petrovic I, Novinscak T, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
- Seiwerth S, Milavic M, Vukojevic J, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159x13666160502153022
